Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment

Veröffentlicht von: pbi
Veröffentlicht am: 28.03.2018 11:38
Rubrik: Gesundheit & Medizin


(Presseportal openBroadcast) - Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Pressekontakt:

Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Overview:
Acute Lymphoblastic Leukemia is a type of cancer which affects white blood cells. It is also called as Acute lymphocytic leukemia. IALL progresses rapidly without treatment. Acute lymphoblastic leukemia (ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. Symptoms of ALL includes fever, anemia, bleeding, blood clots, bone pain, rashes on skin, Palpable lymphadenopathy etc.
ALL is diagnosed by coagulation studies, blood tests, X-Ray, CT-Scan, ECG, MRI, bone marrow aspiration and biopsy etc. Treatment of ALL includes induction chemotherapy, consolidation chemotherapy, Stem cell transplantation and others.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

Segmentation:
By Trial Phase, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:
• Preclinical Trials
• Phase 1
• Phase 2
• Phase 3
• Phase 4
By Company, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:
• Novartis
• Pfizer
• Ariad Pharmaceuticals
• Juno Therapeutics
• Janssen
• Amgen
• (Erytech Pharma
• Bristol-Myers Squibb
• Others
By Drugs, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:
• Blinatumomab
• Carfilzomib
• calaspargasepegol
• Dasatinib
• Ibrutinib
• Inotuzumabozogamicin
• Ofatumumab
• Ponatinib
• Others
By Route of Administration, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:
• Oral
• Parenteral

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu


Space Analysis:
• In October 2015, Seattle Genetics, Inc.initiated randomized phase II clinical trial of denintuzumabmafodotin (SGN-CD19A) in combination with second-line salvage regimen of rituximab (Rituxan), ifosfamide, carboplatin and etoposide (RICE), for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
• In September 2017, Kiadis pharma’s ATR101 was granted Regenerative Medicine Advanced Therapy (RMAT) designation by U.S.FDA and in April 2017, Kiadis pharma received regulatory approval from the national authority in Belgium to start pivotal Phase III trial with ATIR101™ and from the national authority in Germany to start the Phase I/II trial with ATIR201 for patients suffering from blood cancers

Report Description:
Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Acute Lymphoblastic Leukemia treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Acute Lymphoblastic Leukemia disease pipeline drugs development. This report studies the dynamics of the Acute Lymphoblastic Leukemia Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Acute Lymphoblastic Leukemia disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on the each drug candidates in the clinical trial phases

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/
About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,
152 – 160 City Road,
London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com


Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.